The European Commission has approved Kisunla, a treatment for mild cognitive impairments, including dementia in the early stages of Alzheimer's disease. Although the drug, based on the molecule donanemab, has shown promising results in clinical trials, controversy remains regarding its actual benefits and the risks of serious side effects. The authorization is conditional on its administration only to patients without genetic mutations that could increase the risks. EU member states have the freedom to decide on reimbursement, and other countries, such as the United Kingdom, have adopted a similar approach.
Sources
Uniunea Europeană autorizează Kisunla, un tratament al Eli Lilly controversat împotriva maladiei Alzheimer. În afară de beneficii reale modeste, are efecte secundare grave, uneori mortale, şi anume hemoragii şi edeme cerebrale
UE a aprobat un nou medicament pentru Alzheimer
UE a aprobat un nou tratament controversat împotriva Alzheimer
Noi tratamente împotriva Alzheimer: UE a autorizat un medicament promițător, dar cu efecte secundare grave posibile
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
O nouă speranță pentru pacienții cu ALZHEIMER. Comisia Europeană aprobă primul tratament care poate încetini evoluția bolii
Comisia Europeană a autorizat comercializarea unui medicament pentru tratarea bolii Alzheimer în stadii incipiente
Latest News
10:36
Nicușor Dan congratulates the Student List on its historic victory in the elections in Serbia
10:31
Ballon d'Or 2026 / Who will host the gala. What awards will be presented. Which players have been nominated
10:21
Dominic Fritz, after Sorin Grindeanu announced “the de-Securitization of Romania”: “The PSD wants to get rid of those who began changing the rules of the game”
10:15
Ilie Bolojan accuses Sorin Grindeanu of preparing to justify a possible failure to meet the deficit target
10:03
Donald Trump promises a rapid trade agreement with Canada, despite tariffs and tensions between the two countries
See more news